Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Date:3/22/2011

approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile infection.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. There can be no assurance that that the data presented during the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting regarding Cinryze is predictive of how Cinryze will perform in commercial usage.  Cinryze is currently available only in the United States.  Cinryze is not approved in the U.S. for acute treatment of attack, children with HAE or for pre-procedure prophylaxis. We cannot assure that current or future studies with Cinryze in the patient populations described in the AAAAI presentations will demonstrate the same or similar safety and efficacy profile of Cinryze as described in the data presented during the 2011AAAAI. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
2. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
3. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
10. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
11. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Allakos Inc. ... $10 million investment from current investors to fund ... financing was completed following achievement of a key, ... program, and represents an extension of the company,s ... December 2012. With this additional financing, Allakos has ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre 2014 ... Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences (NASDAQ : ... accord de fusion définitif en vertu duquel Daiichi ... ordinaires en circulation d,Ambit Biosciences à 15 dollars ... offre publique d,achat qui sera suivie d,une fusion ...
(Date:9/29/2014)... -- BioMed Realty Trust, Inc. (NYSE: BMR ) ... approximately 200,000 square feet for 12 years with Baxter ... 650 East Kendall Street in Cambridge, Massachusetts ... a joint venture with Prudential Real Estate Investors. Baxter ... and development (R&D) center at the site for its ...
Breaking Medicine Technology:Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9BioMed Realty Trust Signs A New 12-Year Lease Establishing New Innovation And R&D Center In Kendall Square In Cambridge, Massachusetts 2BioMed Realty Trust Signs A New 12-Year Lease Establishing New Innovation And R&D Center In Kendall Square In Cambridge, Massachusetts 3
... Aging Now has been selected by the editors ... fastest-growing private companies. Stop Aging Now , a ... vitamins and supplements. (Logo:   http://photos.prnewswire.com/prnh/20100817/INC5000LOGO ) ... Stop Aging Now was placed in the top ...
... Orthocare Innovations has been honored with the 2010 da ... most innovative technologies for people with disabilities. Orthocare received ... Compas™ is a first-of-its-kind device that lets people with ... to improve the alignment of their prosthesis. The system ...
Cached Medicine Technology:Stop Aging Now Named to Prestigious Inc. 5000 List 2Orthocare Innovations Wins da Vinci Award for Compas™ Computerized Prosthesis Alignment System 2Orthocare Innovations Wins da Vinci Award for Compas™ Computerized Prosthesis Alignment System 3
(Date:9/30/2014)... By Kathleen Doheny ... (HealthDay News) -- Children who are given broad-spectrum antibiotics ... higher risk of becoming obese during childhood, new research ... organisms than narrow-spectrum ones, according to the study. ... need antibiotics, and which antibiotic you are picking," said ...
(Date:9/30/2014)... VA (PRWEB) September 30, 2014 Visit ... of Chestnut Hill and you will find a loving ... together, Amyotrophic Lateral Sclerosis. , Steve was ... or Lou Gehrig’s Disease – just before the couple’s ... primary caregiver. , A new video, “Care, Support ...
(Date:9/30/2014)... September 30, 2014 TrailMyx.com —the ... October Flavor of the Month: raw pumpkin seeds. , ... of squash”)—are rich in protein, and valued by experts ... multiple types of vitamin E. They are prized for ... and proper bowel function. , Of course, pumpkin seeds ...
(Date:9/30/2014)... 30, 2014 Thanks to ... National Children’s Oral Health Foundation: America’s ToothFairy® ... to non-profit clinical partners. These organizations are ... deliver comprehensive educational, preventive and treatment services ...     Just Kids Dental: $25,000 ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- In books and movies, plots ... Now, new research suggests that the stereotype may ... looked at data on more than 12,000 people from Finland. ... in Turku, Finland, found that women typically preferred men who ... consistent throughout their lives. On the other hand, men ...
Breaking Medicine News(10 mins):Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:TrailMyx.com Features October Flavor of the Month 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2
... ALEXANDRIA, Va., Aug. 8 /PRNewswire-USNewswire/ National Hospice and,Palliative ... of the 2008 Circle of Life Award(R). This ... programs that,demonstrate superior vision, depth, and scope., ... American Hospital,Association,s annual summit in San Diego. This ...
... levels of testosterone may be a key factor in ... could help explain why males in a population are ... Previous research has linked testosterone, the male sex hormone, ... compared to females, experience more bouts of disease, and ...
... Children,s Hospital & Research Center Oakland continues to lead ... a new medical journal focused on children and teenagers. ... Pediatric Rehabilitation Department, is the founder and editor-in-chief of ... Approach . The quarterly journal released its second issue ...
... Eastern Insurance,Holdings, Inc. (Nasdaq: EIHI ... has executed a definitive agreement to acquire ... a transaction valued at,approximately $14.9 million, including ... wholly owned subsidiary is Employers Security Insurance,Company, ...
... of victims get to hospital quickly enough to limit damage, ... people who have strokes don,t act quickly enough to get ... study finds. , "One of the problems is that a ... stroke," said Kathryn M. Rose, a research associate professor of ...
... Aug. 7 Vapotherm, the,global leader in High ... the Food and Drug Administration (FDA) for Precision,Flow(TM), ... gas,blending, flow control and humidification technology into one ... gases., Other Vapotherm products are currently used ...
Cached Medicine News:Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 2Health News:Circle of Life Awards Recognize Innovative End-of-Life Care Providers 3Health News:Testosterone key to disease transmission 2Health News:Children's Hospital Oakland publishes first of its kind pediatric rehabilitation journal 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 2Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 3Health News:Eastern Insurance Holdings, Inc. Announces Definitive Agreement to Acquire Employers Security Holding Company and Subsidiaries 4Health News:Many Miss Out on Stroke Treatment 2Health News:Many Miss Out on Stroke Treatment 3Health News:Vapotherm(R) Precision Flow(TM) Receives FDA 510(k) Clearance 2
... Model V-1000 is a new addition to the ... This high performance pump can achieve an ultimate ... of 64 L/min. Applications For ... concentrators Distillation applications from lab size ...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
... The OFP400 Oil-free Vacuum Pump is designed for ... high chemical resistance, quiet running and eliminates oil ... any oil to operate. Less mess, less fuss., ... 4-headed design with chemically resistant solid ETFE and ...
... several different two-stage, oil-sealed, rotary vane vacuum ... applications. Each pump comes complete with a ... and Oil Mist Filter (EMF-10). The GBORK ... ballast to keep the oil clean without ...
Medicine Products: